125 Cambridgepark Drive Cambridge, MA 02140 +1 877.848.9903
Machine Learning and Artificial Intelligence Empowers life sciences companies to identify, engage and activate patients who could benefit from new therapies and modalities of care
CAMBRIDGE, MA. – March 10, 2020 - IPM.ai, an emerging leader in discovering ideal patient populations though the use of machine learning and artificial intelligence, today announced the general availability of the pharmaceutical industry's first system of insight. The offering utilizes machine learning, artificial intelligence and granular-level longitudinal analysis in conjunction with an enriched and tokenized data pool of over 300 million de-identified patients to revolutionize patient discovery, healthcare provider intelligence, key opinion leader identification, treatment journey mapping, market segmentation, study recruitment and audience engagement. The system is back by a seasoned team of highly-experienced life sciences experts, healthcare professionals and data scientists
Specialty and rare diseases have undefined patient populations, with patients who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as treatment journeys that are not well-understood”, said Ron Elwell, CEO and co-founder of IPM.ai. “Until now, no one in the industry had the necessary technology, capabilities and domain expertise to help pharmaceutical and biopharmaceutical companies identify, engage and activate patients who could benefit from new therapies and modalities of care”.
In addition to is core data pool, IPM.ai can easily ingest, transform and unify additional data streams of any scale thus leveraging a client’s investments in EMR, lab, genetic and clinical trial data. This capability is due to a partnership with Universal Patient Key (UPK), a cutting-edge, portable and HIPAA-compliant token vendor.
“We are excited to be partnering with IPM.ai to bring a portable, scalable, and differentiated offering to the market,” said Shahir Kassam-Adams, CEO of UPK. “Their core use cases – rare disease patient finding, predicting patient journey progression across rarel and specialty markets, clinical trial recruiting, enabling precision medicine in oncology, adherence issues – are all incredibly valuable offerings for our customers. The industry has really never seen this combination of capabilities before, and we’re proud to be powering IPM.ai in their groundbreaking endeavor.”
IPM.ai is an Insights as a Service (IaaS) company that empowers the world’s leading life sciences brands to better understand and improve the lives of patients through the research, development and commercialization of new therapies and modalities of care for specialty and rare disease. IPM.ai’s system of insight streamlines patient discovery, treatment journey mapping, referral network intelligence, key opinion leader identification, market segmentation and adherence modeling by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data, social determinants of health and outcomes research pool of over 300 million de-identified patients.
Chief Marketing Officer
Leveraging the power of RWD and AI to identify, engage and activate ideal patient populations who could benefit from new therapies and modalities of care.
Subscribe to our newsletter for the latest company updates, industry developments, and media coverage.